Senti Biosciences (SNTI) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company developing next-generation cell and gene therapies using a synthetic biology platform called gene circuits for enhanced precision and control in targeting incurable diseases.

• Pipeline includes off-the-shelf CAR-NK cells for liquid and solid tumors, with lead program SENTI-202 showing complete remissions in two of three patients in initial clinical data as of September 19, 2024.

• Strategic collaborations with Roche/Spark Therapeutics, Bayer/BlueRock Therapeutics, and Celest Therapeutics for broader application of gene circuits.

• Incorporated in Delaware in 2016, principal offices in South San Francisco, CA, and listed on Nasdaq under the symbol "SNTI."

Financial performance and metrics

• As of March 19, 2025, public float was approximately $57.81 million based on 25,986,000 outstanding shares and a price of $3.62 per share.

• Company has incurred recurring losses, negative cash flows from operations, and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern.

• Independent auditor included a going concern explanatory paragraph in the 2024 financial statements.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for working capital and general corporate purposes, including R&D, clinical trials, manufacturing, and capital expenditures.

• Management retains broad discretion over allocation and timing of proceeds, which may be temporarily invested in capital preservation instruments.